that emerged in the UK with the second COVID-19 wave in late 2020. The efficacy of currently
licensed COVID-19 vaccines against B. 1.617. 2 is unknown; although it possesses 12 …

… Wall, Emma C. a,b ; Chan, Jia Mun b ; Gil, Eliza b ; Heyderman, Robert S. b … Wall,
NE424, Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK. Tel: +44 203 7960000; …

Objective The current study examined and compared perceptions of illness in individuals
with anorexia nervosa (AN) and lay men and women. Method Participants with AN (n = 95) …

Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring
(CAPTURE) ( NCT03226886 ) is a prospective cohort study of COVID-19 immunity in …

The SARS-CoV-2 B. 1.617. 2 Delta variant of concern (VOC) continues to drive a sharp increase
in COVID-19 cases in the UK, with a current doubling time of 3· 5–16 days, 1 consistent …

We sought to compare neutralising antibody responses between seronaive haemodialysis
patients and the healthy individuals we have already reported on as part of the Legacy study. …

Progress has been made in the prevention and treatment of community-acquired bacterial
meningitis during the past three decades but the burden of the disease remains high globally. …

Background. Therapy for human immunodeficiency virus (HIV)–associated cryptococcal
meningitis in many centers in Africa is fluconazole administered at a dosage of 400–800 mg per …

Background Every day children and adults die from acute community‐acquired bacterial
meningitis, particularly in low‐income countries, and survivors risk deafness, epilepsy and …

Patients with cancer are at greater risk of severe COVID-19 and have been prioritised for
COVID-19 vaccination globally. We previously showed that following two doses of COVID-19 …